Raymond James Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $6

Raymond James analyst Thomas Deal has initiated coverage on Palisade Bio (NASDAQ: PALI) with an Outperform rating. The firm has set a price target of $6 for the company's stock.